TELO
Telomir Pharmaceuticals, Inc.
Price Chart
Latest Quote
$1.42
+0.17 (+13.60%)
Current Price
| Previous Close | $1.25 |
| Open | $1.29 |
| Day High | $1.43 |
| Day Low | $1.29 |
| Volume | 1,079,993 |
Stock Information
| Shares Outstanding | 68.77M |
| Total Debt | $203K |
| Cash Equivalents | $5.56M |
| Net Income | $-9.22M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $97.66M |
| EPS (TTM) | $-0.29 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $82.67M |
| Income | $-9.22M |
| Book/sh | $0.17 |
| Cash/sh | $0.08 |
Financial Ratios
| Quick Ratio | 6.72 |
| Current Ratio | 7.00 |
| Debt/Eq | 4.09 |
Returns & Margins
| ROA | -186.93% |
| ROE | -384.26% |
Ownership
| Insider Ownership | 35.10% |
| Institutional Ownership | 3.26% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.07 |
| P/B | 8.26 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.27 |
| SMA50 | $1.31 |
| SMA200 | $1.35 |
| RSI | 60.00 |
| ATR | 0.0715 |
| Shares Float | 38.06M |
| Short Float | 1.67% |
| Short Ratio | 4.32 |
| Rel Volume | 7.61 |
Performance History
| Week | +12.70% |
| Month | +16.39% |
| Quarter | +7.58% |
| 6 Months | +1.43% |
| YTD | +5.97% |
| Year | -23.66% |
| 10 Years | -71.60% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.42 | 1,079,993 |
| 2026-06-17 | $1.25 | 115,500 |
| 2026-06-16 | $1.28 | 130,600 |
| 2026-06-15 | $1.29 | 124,600 |
| 2026-06-12 | $1.26 | 142,400 |
| 2026-06-11 | $1.26 | 82,100 |
| 2026-06-10 | $1.24 | 76,500 |
| 2026-06-09 | $1.21 | 52,900 |
| 2026-06-08 | $1.28 | 116,700 |
| 2026-06-05 | $1.21 | 73,300 |
| 2026-06-04 | $1.27 | 35,000 |
| 2026-06-03 | $1.23 | 74,000 |
| 2026-06-02 | $1.24 | 79,200 |
| 2026-06-01 | $1.25 | 183,800 |
| 2026-05-29 | $1.30 | 128,300 |
| 2026-05-28 | $1.28 | 87,100 |
| 2026-05-27 | $1.29 | 41,700 |
| 2026-05-26 | $1.29 | 75,900 |
| 2026-05-22 | $1.29 | 53,900 |
| 2026-05-21 | $1.30 | 86,400 |
| 2026-05-20 | $1.31 | 107,800 |
| 2026-05-19 | $1.22 | 118,400 |
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $4,338,542 | $1,643,049 | $0 |
| Total Expenses | $10,538,849 | $12,242,174 | $3,942,048 | $854,147 |
| Net Non Operating Interest Income Expense | $125,644 | $-4,290,542 | $-1,643,049 | $0 |
| Interest Expense Non Operating | $0 | $4,338,542 | $1,643,049 | $0 |
| Operating Expense | $10,538,849 | $12,242,174 | $3,942,048 | $854,147 |
| General And Administrative Expense | $8,103,280 | $9,636,333 | $600,192 | $20,941 |
| Other Operating Expenses | - | $370,500 | $1,767,550 | - |
| Other Income Expense | - | - | $-7,486,767 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-10,413,205 | $-16,532,716 | $-13,071,864 | $-854,147 |
| Net Interest Income | $125,644 | $-4,290,542 | $-1,643,049 | $0 |
| Interest Income | $125,644 | $48,000 | $0 | - |
| Normalized Income | $-10,413,205 | $-16,532,716 | $-5,585,097 | $-854,147 |
| Net Income From Continuing And Discontinued Operation | $-10,413,205 | $-16,532,716 | $-13,071,864 | $-854,147 |
| Net Income Common Stockholders | $-10,413,205 | $-16,532,716 | $-13,071,864 | $-854,147 |
| Net Income | $-10,413,205 | $-16,532,716 | $-13,071,864 | $-854,147 |
| Net Income Including Noncontrolling Interests | $-10,413,205 | $-16,532,716 | $-13,071,864 | $-854,147 |
| Net Income Continuous Operations | $-10,413,205 | $-16,532,716 | $-13,071,864 | $-854,147 |
| Pretax Income | $-10,413,205 | $-16,532,716 | $-13,071,864 | $-854,147 |
| Interest Income Non Operating | $125,644 | $48,000 | $0 | - |
| Operating Income | $-10,538,849 | $-12,242,174 | $-3,942,048 | $-854,147 |
| Special Income Charges | - | $0 | $-7,486,767 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.33 | $-0.56 | $-0.44 | $-0.03 |
| Basic EPS | $-0.33 | $-0.56 | $-0.44 | $-0.03 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-10,413,205 | $-12,194,174 | $-3,942,048 | $-854,147 |
| EBITDA (Bullshit earnings) | $-10,413,205 | $-12,194,174 | $-11,428,815 | $-854,147 |
| EBIT | $-10,413,205 | $-12,194,174 | $-11,428,815 | $-854,147 |
| Diluted Average Shares | $31,653,094 | $29,539,219 | $29,609,814 | $29,609,814 |
| Basic Average Shares | $31,653,094 | $29,539,219 | $29,609,814 | $29,609,814 |
| Diluted NI Availto Com Stockholders | $-10,413,205 | $-16,532,716 | $-13,071,864 | $-854,147 |
| Research And Development | $2,435,569 | $2,235,341 | $1,574,306 | $833,206 |
| Selling General And Administration | $8,103,280 | $9,636,333 | $600,192 | $20,941 |
| Other Gand A | $8,103,280 | $9,636,333 | $600,192 | $20,941 |
| Total Unusual Items | - | $0 | $-7,486,767 | $0 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-7,486,767 | $0 |
| Other Special Charges | - | - | $7,486,767 | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,913,370 | $643,037 | $3,438,204 | $-937,278 |
| Total Assets | $7,341,361 | $1,324,005 | $4,773,768 | $48,730 |
| Total Non Current Assets | $0 | $0 | $4,338,543 | $0 |
| Current Assets | $7,341,361 | $1,324,005 | $435,225 | $48,730 |
| Prepaid Assets | $54,691 | $57,874 | $713 | $0 |
| Cash Cash Equivalents And Short Term Investments | $7,286,670 | $1,266,131 | $1,231 | $1,419 |
| Cash And Cash Equivalents | $7,286,670 | $1,266,131 | $1,231 | $1,419 |
| Cash Financial | $7,286,670 | $1,266,131 | $1,231 | $1,419 |
| Non Current Deferred Assets | - | $0 | $4,338,543 | $0 |
| Current Deferred Assets | - | $0 | $303,281 | $47,311 |
| Receivables | - | $0 | $130,000 | $0 |
| Debt | ||||
| Net Debt | - | - | $99,769 | - |
| Total Debt | - | - | $101,000 | - |
| Current Debt And Capital Lease Obligation | - | - | $101,000 | - |
| Current Debt | - | - | $101,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,427,991 | $680,968 | $1,335,564 | $986,008 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $1,427,991 | $680,968 | $1,335,564 | $986,008 |
| Payables And Accrued Expenses | $1,427,991 | $680,968 | $1,234,564 | $986,008 |
| Payables | $1,010,521 | $680,968 | $1,234,564 | $986,008 |
| Accounts Payable | $536,769 | $587,536 | $707,187 | $404,221 |
| Equity | ||||
| Common Stock Equity | $5,913,370 | $643,037 | $3,438,204 | $-937,278 |
| Total Equity Gross Minority Interest | $5,913,370 | $643,037 | $3,438,204 | $-937,278 |
| Stockholders Equity | $5,913,370 | $643,037 | $3,438,204 | $-937,278 |
| Retained Earnings | $-41,010,063 | $-30,596,858 | $-14,064,142 | $-992,278 |
| Other Equity Interest | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $34,380,971 | $29,762,671 | $29,609,814 | $29,609,814 |
| Share Issued | $34,380,971 | $29,762,671 | $29,609,814 | $29,609,814 |
| Tangible Book Value | $5,913,370 | $643,037 | $3,438,204 | $-937,278 |
| Invested Capital | $5,913,370 | $643,037 | $3,539,204 | $-937,278 |
| Working Capital | $5,913,370 | $643,037 | $-900,339 | $-937,278 |
| Total Capitalization | $5,913,370 | $643,037 | $3,438,204 | $-937,278 |
| Additional Paid In Capital | $46,923,433 | $31,239,895 | $17,502,346 | $55,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Accrued Expenses | $417,470 | $0 | - | - |
| Dueto Related Parties Current | $473,752 | $93,432 | $527,377 | $581,787 |
| Line Of Credit | - | $0 | $101,000 | $0 |
| Duefrom Related Parties Current | - | $0 | $130,000 | $0 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,688,188 | $-5,070,428 | $-3,859,796 | $-468,661 |
| Operating Activities | ||||
| Operating Cash Flow | $-3,688,188 | $-5,070,428 | $-3,859,796 | $-468,661 |
| Cash Flow From Continuing Operating Activities | $-3,688,188 | $-5,070,428 | $-3,859,796 | $-468,661 |
| Operating Gains Losses | - | - | $7,486,767 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $9,553,209 | $6,832,973 | $1,000,000 | $0 |
| Financing Cash Flow | $9,708,727 | $6,335,328 | $3,859,608 | $470,080 |
| Cash Flow From Continuing Financing Activities | $9,708,727 | $6,335,328 | $3,859,608 | $470,080 |
| Net Common Stock Issuance | $9,553,209 | $6,832,973 | $1,000,000 | $0 |
| Common Stock Issuance | $9,553,209 | $6,832,973 | $1,000,000 | $0 |
| Net Other Financing Charges | - | $-433,945 | $1,407,194 | $7,689 |
| Other | ||||
| Repayment Of Debt | $0 | $-101,000 | $0 | - |
| Issuance Of Debt | $155,518 | $0 | $1,452,414 | $462,391 |
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | - |
| End Cash Position | $7,286,670 | $1,266,131 | $1,231 | $1,419 |
| Beginning Cash Position | $1,266,131 | $1,231 | $1,419 | $0 |
| Changes In Cash | $6,020,539 | $1,264,900 | $-188 | $1,419 |
| Proceeds From Stock Option Exercised | $0 | $37,300 | $0 | - |
| Net Issuance Payments Of Debt | $155,518 | $-101,000 | $1,452,414 | $462,391 |
| Net Short Term Debt Issuance | $155,518 | $-101,000 | $1,452,414 | $462,391 |
| Short Term Debt Payments | $0 | $-101,000 | $0 | - |
| Short Term Debt Issuance | $155,518 | $0 | $1,452,414 | $462,391 |
| Change In Working Capital | $594,688 | $126,469 | $113,843 | $385,486 |
| Change In Other Working Capital | $224,802 | - | - | - |
| Change In Payables And Accrued Expense | $366,703 | $183,629 | $114,556 | $385,486 |
| Change In Prepaid Assets | $3,183 | $-57,160 | $-713 | $0 |
| Stock Based Compensation | $6,130,329 | $6,867,276 | $0 | - |
| Net Income From Continuing Operations | $-10,413,205 | $-16,532,716 | $-13,071,864 | $-854,147 |
| Other Non Cash Items | - | $4,468,543 | $1,611,458 | - |
Fetched: 2026-06-16